BGS649 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pelvic Pain Associated With Refractory Endometriosis
Conditions
Pelvic Pain Associated With Refractory Endometriosis
Trial Timeline
Apr 15, 2010 → Mar 21, 2012
NCT ID
NCT01116440About BGS649 + Placebo
BGS649 + Placebo is a phase 2 stage product being developed by Novartis for Pelvic Pain Associated With Refractory Endometriosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01116440. Target conditions include Pelvic Pain Associated With Refractory Endometriosis.
What happened to similar drugs?
3 of 6 similar drugs in Pelvic Pain Associated With Refractory Endometriosis were approved
Approved (3) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01116440 | Phase 2 | Terminated |
Competing Products
11 competing products in Pelvic Pain Associated With Refractory Endometriosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solifenacin + Placebo | Astellas Pharma | Approved | 35 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 35 |
| Azithromycin | Pfizer | Phase 3 | 40 |
| Vaginal estrogen + Placebo | Pfizer | Pre-clinical | 18 |
| Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet | Pfizer | Phase 2 | 27 |
| Conjugated Estrogens Cream + Placebo Cream | Pfizer | Approved | 43 |
| BAY1834845 + Placebo | Bayer | Phase 1 | 26 |
| Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) | Bayer | Phase 3 | 37 |
| Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole | Bayer | Phase 3 | 37 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 23 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 40 |